Amrita Jain
Private Equity Investor chez LongeVC
Profil
Amrita Jain is Principle at LongeVC, a venture capital company backing visionary biotech.
Before joining LongeVC, Amrita worked at Fusix Biotech, a pre-clinical-stage biotechnology company developing a next-generation oncolytic virus platform to treat patients across multiple tumour types.
She was also a Business Development Manager for cancer immunotherapy company Immatics Biotechnologies and an Investment Analyst at venture capital fund Life Science Partners ( LSP).
Amrita holds a Master's degree in Genome Sciences/Genomics from Madurai Kamaraj University and a PhD in Biochemistry and Molecular Biology from the University of Utrecht.
Postes actifs de Amrita Jain
| Sociétés | Poste | Début |
|---|---|---|
LongeVC
 LongeVC Investment ManagersFinance LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland. | Private Equity Investor | 01/03/2021 |
Anciens postes connus de Amrita Jain
| Sociétés | Poste | Fin |
|---|---|---|
Fusix Biotech GmbH
 Fusix Biotech GmbH BiotechnologyHealth Technology Fusix Biotech GmbH is a private company located in Germany that aims to deliver breakthrough cancer immunotherapies utilizing a unique "fusogenic" mechanism of action to directly kill tumor cells, heat up the tumor microenvironment, and mediate systemic immune effects to target tumor cells throughout the body. The German company is still part of the Klinikum rechts der Isar of the Technical University Munich and is currently planning to spin-out in 2022. The Fusix technology offers a unique mechanism of action that will revolutionize immune oncology in solid cancers by converting the tumor microenvironment from an immune suppressed “cold” tumor into an immune-sensitized “hot” tumor infiltrated with immunotherapeutics. | Corporate Officer/Principal | 30/04/2022 |
| LSP Services Deutschland GmbH | Analyste en capital-investissement | 28/02/2020 |
Bavarian Nordic GmbH
 Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Corporate Officer/Principal | 01/01/2019 |
Formation de Amrita Jain
| University of Utrecht | Doctorate Degree |
| Madurai Kamaraj University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
| LSP Services Deutschland GmbH | Finance |
LongeVC
LongeVC Investment ManagersFinance LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland. | Finance |
Fusix Biotech GmbH
Fusix Biotech GmbH BiotechnologyHealth Technology Fusix Biotech GmbH is a private company located in Germany that aims to deliver breakthrough cancer immunotherapies utilizing a unique "fusogenic" mechanism of action to directly kill tumor cells, heat up the tumor microenvironment, and mediate systemic immune effects to target tumor cells throughout the body. The German company is still part of the Klinikum rechts der Isar of the Technical University Munich and is currently planning to spin-out in 2022. The Fusix technology offers a unique mechanism of action that will revolutionize immune oncology in solid cancers by converting the tumor microenvironment from an immune suppressed “cold” tumor into an immune-sensitized “hot” tumor infiltrated with immunotherapeutics. | Health Technology |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Health Technology |